{"prompt": "['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Appendix C: Memorial Sloan Kettering Cancer Center (MSKCC) Criteria', 'Criterion', 'Points', 'Karnofsky performance status 70%', '(No - 0; Yes - 1)', 'Time from diagnosis to treatment < 1 year', '(No 0; Yes - 1)', 'Hemoglobin concentration < LLN', '(No 0; Yes - 1)', 'Serum corrected calcium concentration > 10 mg/dl (> 2.5 mmol/L)', '(No 0; Yes - 1)', 'Lactate dehydrogenase level > 1.5x ULN', '(No - 0; Yes - 1)', 'Favorable risk group: 0 points.', 'Intermediate risk group: 1-2 points.', 'Poor risk group: 3-5 points.', 'Page 51 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'Appendix D: Response Evaluation Criteria in Solid Tumors (RECIST)', 'Version 1.1', 'Definitions', 'Baseline: Baseline is defined as the most recent assessment performed prior to initiation of study', 'treatment.', 'Baseline assessments must be performed within the period defined in the protocol.', 'Measurable lesions: Except for lymph nodes as described below, measurable lesions are defined as', 'those that can be accurately measured in at least 1 dimension (longest diameter to be recorded) as', '10 mm with CT scan (if CT scans have slice thickness greater than 5 mm the minimum size for a', 'measurable lesion is twice the slice thickness).', 'To be considered pathologically enlarged and measurable, a lymph node must be 15 mm in short', 'axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than 5 mm).', 'At baseline and in follow-up, only the short axis will be measured and recorded.', 'MRI may be substituted for contrast-enhanced CT for lesions at some anatomical sites, but not for', 'lesions in the lungs. The minimum size for measurability is the same as for CT (10 mm) as long as the', 'scans are performed with slice thickness of 5 mm and no gap. If MRI is performed with thicker slices,', 'the size of a measurable lesion at baseline should be twice the slice thickness. In the event there are', 'interslice gaps, this also needs to be considered in determining the size of measurable lesions at', 'baseline.', 'Nonmeasurable lesions: All other lesions (or sites of disease), including small lesions (longest', 'diameter < 10 mm or pathological lymph nodes with >10 to < 15 mm short axis), are considered', 'nonmeasurable. Lymph nodes that have a short axis < 10 mm are considered nonpathological and', 'are not be recorded or followed. Bone lesions, leptomeningeal disease, ascites, pleural/pericardial', 'effusions, lymphangitis cutis/ pulmonitis, inflammatory breast disease, and abdominal masses (not', 'followed by CT or MRI), are considered as nonmeasurable.', 'Target lesions: All measurable lesions up to a maximum of 2 lesions per organ and 5 lesions in total,', 'representative of all involved organs, are to be identified as target lesions and measured and', 'recorded at baseline. Target lesions are to be selected on the basis of their size (lesions with the', 'longest diameter), be representative of all involved organs, and be those that lend themselves to', 'reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does', 'not lend itself to reproducible measurement in which circumstance the next largest lesion which can', 'be measured reproducibly should be selected. Target lesions will be measured at each assessment', '(longest axis for nonnodal lesions, shortest axis for measurable malignant nodal lesions).', 'Nontarget lesions: All other lesions (or sites of disease) including all non-measurable lesions', '(including pathological lymph nodes with 10 to <15 mm short axis) and all measurable lesions over', 'and above the 5 target lesions are to be identified as non-target lesions and recorded at baseline.', 'Measurements of these lesions are not required, but the presence, absence, or in rare cases', 'unequivocal progression of each is to be recorded throughout follow-up. Lymph nodes that have a', 'short axis < 10mm are considered non-pathological and are not to be recorded or followed.', 'To be considered progression of non-target lesions in the presence of measurable disease,', 'unequivocal progression is defined as substantial worsening in non-target disease such that, even in', 'Page 52 of 60']['Protocol Identifying Number: PS-001', 'Protocol Version: 1.0', 'Protocol Date: 10 Sep 2017', 'the presence of SD or PR in target disease, the overall tumor burden has increased sufficiently to', 'merit discontinuation of the therapy.', 'Special Consideration', 'Lesions by clinical examination will not be used for response in this study.', 'Cystic lesions', 'Cystic lesions that meet the criteria for radiographically defined simple cysts should not be', 'considered as malignant lesions (neither measurable nor nonmeasurable) since they are, by', 'definition, simple cysts.', 'Cystic lesions thought to represent cystic metastases can be considered as measurable lesions, if', 'they meet the definition of measurability described above. However, if noncystic lesions are present', 'in the same patient, these are preferred for selection as target lesions.', 'Bone lesions', 'Bone scan, PET scan or plain films are not considered adequate imaging techniques to measure', 'bone lesions. However, these techniques can be used to confirm the presence or disappearance of', 'bone lesions.', 'Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components, that can', 'be evaluated by cross-sectional imaging techniques such as CT or MRI can be considered as', 'measurable lesions if the soft tissue component meets the definition of measurability described', 'above.', 'Blastic bone lesions are non-measurable.', 'Lesions with prior local treatment', 'Lesions situated in a previously irradiated area, or in an area subjected to other loco-regional', 'therapy, are not considered measurable.', 'Imaging Methods', 'The same method of assessment and the same technique used to characterize each identified and', 'reported lesions at baseline should be used during each follow-up assessment. All measurements', 'should be taken and recorded in metric notation using a ruler or calipers. Imaging based evaluation is', 'preferred to evaluation by clinical examination unless the lesion(s) being followed cannot be imaged', 'but assessed by clinical examination (referring to biopsy-proven visible lesion(s) on the chest).', 'Chest x-ray: Chest x-ray will not be used for response assessment in this study.', 'Conventional CT and MRI: This guideline has defined measurability of lesions on CT scan based on the', 'assumption that CT slice thickness is 5 mm or less. If CT scans have slice thickness greater than 5 mm,', 'the minimum size for a measurable lesion is twice the slice thickness. MRI is also acceptable in', 'certain situations (eg, for body scan) except for lung.', 'Use of MRI remains a complex issue. MRI has excellent contrast, spatial, and temporal resolution;', 'however, there are many image acquisition variables involved in MRI, which greatly impact image', 'quality, lesion conspicuity, and measurement. Furthermore, the availability of MRI is variable', 'globally. As with CT, if an MRI is performed, the technical specifications of the scanning sequences', 'Page 53 of 60']\n\n###\n\n", "completion": "END"}